Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Brought to you by:
European Medicines Agency
Biotech
Minoryx knocked back by EMA but vows to seek rerun of review
EMA swatted away Minoryx’s attempt to bring a rare disease candidate to market on the strength of a clinical trial that missed its primary endpoint.
Nick Paul Taylor
Jan 26, 2024 8:40am
Arcturus sa-mRNA COVID boosters induce immune response in ph. 2
Sep 19, 2023 11:40am
EMA gives support to Duchenne trial simulation platform
Jan 26, 2023 5:00am
EMA clears barrier on road to landmark Vertex-CRISPR approval
Jan 25, 2023 8:20am
As Sanofi's SERD falls, Menarini's advances with EU review
Aug 19, 2022 9:20am
3 patients hospitalized in uniQure Huntington's disease trial
Aug 8, 2022 11:45am
